The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Final week, the U.S. Meals and Drug Administration (FDA) accredited the usage of Darzalex Faspro (daratumumab and hyaluronidase-fihj) together with Velcade (bortezomib),...
Dr. Myron Czuczman highlighted the importance of the current U.S. Meals and Drug Administration (FDA) approval of Lymphir (denileukin diftitox-cxdl) for sufferers...
